Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$2.10 +1.0%	$3.12	$2.06 ▼ $5.64	$139.70M	1.29	1.27 million shs	862,176 shs
RZLT Rezolute	$7.12 -1.4%	$5.72	$2.21 ▼ $7.46	$619.41M	0.02	729,348 shs	1.26 million shs
TERN Terns Pharmaceuticals	$6.96 -1.6%	$5.58	$1.87 ▼ $11.40	$609.08M	-0.04	1.16 million shs	912,087 shs
XNCR Xencor	$8.13 +1.0%	$8.29	$6.92 ▼ $27.24	$579.86M	0.82	743,533 shs	769,384 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	0.00%	-9.48%	-11.39%	-37.13%	-8.30%
RZLT Rezolute	0.00%	+1.71%	+19.66%	+74.08%	+52.46%
TERN Terns Pharmaceuticals	0.00%	+0.43%	+19.38%	+123.08%	-9.61%
XNCR Xencor	0.00%	-3.33%	-2.28%	+5.58%	-52.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	2.0817 of 5 stars	3.4	1.0	0.0	2.7	1.7	0.6
RZLT Rezolute	3.4357 of 5 stars	3.6	3.0	0.0	4.0	4.2	0.0
TERN Terns Pharmaceuticals	3.8844 of 5 stars	3.3	1.0	4.1	3.0	3.3	0.0
XNCR Xencor	3.6582 of 5 stars	3.4	0.0	3.9	2.8	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.83	Moderate Buy	$10.10	380.95% Upside
RZLT Rezolute	3.17	Buy	$12.50	75.56% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	124.50% Upside
XNCR Xencor	2.75	Moderate Buy	$23.71	191.69% Upside

Current Analyst Ratings Breakdown

Latest CRDF, RZLT, TERN, and XNCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	XNCR Xencor	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $15.00
8/7/2025	XNCR Xencor	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $27.00
8/7/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$31.00 ➝ $26.00
8/6/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $10.00
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	205.46	N/A	N/A	$1.86 per share	1.13
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.07 per share	N/A
XNCR Xencor	$110.49M	5.25	N/A	N/A	$9.63 per share	0.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.87	N/A	N/A	N/A	-9,344.14%	-77.94%	-63.65%	11/6/2025 (Estimated)
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	9/18/2025 (Estimated)
TERN Terns Pharmaceuticals	-$88.85M	-$1.04	N/A	N/A	N/A	N/A	-27.35%	-26.18%	11/11/2025 (Estimated)
XNCR Xencor	-$232.62M	-$2.40	N/A	N/A	N/A	-121.52%	-25.75%	-18.19%	11/5/2025 (Estimated)

Latest CRDF, RZLT, TERN, and XNCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/18/2025	Q4 2025	RZLT Rezolute	-$0.22	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	XNCR Xencor	-$0.78	-$0.41	+$0.37	-$0.41	$22.59 million	$43.61 million
8/5/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A
7/29/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	-$0.21	-$0.02	-$0.21	$0.11 million	$0.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	4.42	4.42
RZLT Rezolute	N/A	8.43	8.43
TERN Terns Pharmaceuticals	N/A	24.70	24.70
XNCR Xencor	N/A	5.34	5.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
RZLT Rezolute	82.97%
TERN Terns Pharmaceuticals	98.26%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
RZLT Rezolute	18.39%
TERN Terns Pharmaceuticals	1.50%
XNCR Xencor	5.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
RZLT Rezolute	40	87.00 million	71.00 million	Optionable
TERN Terns Pharmaceuticals	40	87.51 million	86.20 million	Not Optionable
XNCR Xencor	280	71.32 million	67.59 million	Optionable

CRDF, RZLT, TERN, and XNCR Headlines

Recent News About These Companies

Price T Rowe Associates Inc. MD Decreases Position in Xencor, Inc. $XNCR

August 30 at 4:22 AM | marketbeat.com

Invesco Ltd. Raises Holdings in Xencor, Inc. $XNCR

August 29 at 3:23 AM | marketbeat.com

Xencor to Participate at Upcoming Investor Conferences

August 27, 2025 | businesswire.com

Vanguard Group Inc. Trims Stake in Xencor, Inc. $XNCR

August 26, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives $23.71 Consensus Target Price from Brokerages

August 25, 2025 | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by Analysts

August 24, 2025 | marketbeat.com

Aberdeen Group plc Grows Holdings in Xencor, Inc. $XNCR

August 23, 2025 | marketbeat.com

Royal Bank Of Canada Lowers Xencor (NASDAQ:XNCR) Price Target to $15.00

August 23, 2025 | americanbankingnews.com

Xencor, Inc. $XNCR Stock Holdings Lifted by Public Sector Pension Investment Board

August 22, 2025 | marketbeat.com

Xencor price target lowered to $15 from $32 at RBC Capital

August 21, 2025 | msn.com

Q3 Earnings Estimate for Xencor Issued By Leerink Partnrs

August 11, 2025 | marketbeat.com

Wedbush Estimates Xencor's Q3 Earnings (NASDAQ:XNCR)

August 11, 2025 | marketbeat.com

William Blair Analysts Boost Earnings Estimates for Xencor

August 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.37 EPS

August 10, 2025 | marketbeat.com

Xencor (XNCR) Receives a Buy from Leerink Partners

August 9, 2025 | theglobeandmail.com

Xencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

August 9, 2025 | finance.yahoo.com

Xencor (XNCR) Q2 Revenue Jumps 82%

August 9, 2025 | theglobeandmail.com

Xencor (NASDAQ:XNCR) Hits New 12-Month Low on Analyst Downgrade

August 8, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Given New $27.00 Price Target at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Wedbush Lowers Xencor (NASDAQ:XNCR) Price Target to $26.00

August 8, 2025 | marketbeat.com

Xencor price target lowered to $26 from $31 at Wedbush

August 8, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CRDF, RZLT, TERN, and XNCR Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$2.10 +0.02 (+0.96%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.12 +0.02 (+0.71%)

As of 08/29/2025 07:52 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Rezolute NASDAQ:RZLT

$7.12 -0.10 (-1.39%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$7.09 -0.03 (-0.48%)

As of 08/29/2025 07:50 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Terns Pharmaceuticals NASDAQ:TERN

$6.96 -0.11 (-1.56%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$6.96 0.00 (0.00%)

As of 08/29/2025 06:49 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Xencor NASDAQ:XNCR

$8.13 +0.08 (+0.99%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$8.13 0.00 (0.00%)

As of 08/29/2025 06:43 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time